News | November 07, 2024
Alembic Pharmaceuticals Q2 FY25 PAT up 12% to Rs. 153 Cr
US Generics grew 5% to Rs. 467 Crores for the quarter
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue share from the North America increased to 79% in Q2 FY25 as compared to 67% in Q2 FY24
He has 35+ years of experience in understanding of business and products, analytical ability, eye for detail and computer literacy and knowledge of recent trends.
The US District Court of New Jersey decided to grant a preliminary injunction delaying the launch of LEQSELVI
Granules now has a total of 67 ANDA approvals from the USFDA
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
Aims to achieve CDMO sales of US$ 400 million by 2028
Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic
USFDA completes PAI of Lupin’s biotech facility in Pune
Based on ECHO Phase III trial which demonstrated Calquence combination reduced risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy
Subscribe To Our Newsletter & Stay Updated
